Patients will inject themselves once a week with pens pre-filled with semaglutide, also know as Wegovy. The drug will be offered alongside a reduced calorie diet and increased physical activity to adults who have at least one weight-related health condition and a body mass index (BMI) of at least 35kg/m2.
Those with a BMI of between 30-34.9kg/m2 could also be prescribed the drug if they have a weight-related health condition, the agency said.
Helen Knight, director of medicines evaluation at NICE, said: “For some people losing weight is a real challenge which is why a medicine like semaglutide is a welcome option…
